Literature DB >> 23040111

Genetic variants of the renin-angiotensin-aldosterone system and reverse remodeling after cardiac resynchronization therapy.

Renata De Maria1, Maurizio Landolina, Maurizio Gasparini, Boris Schmitz, Jonica Campolo, Marina Parolini, Antonio Sanzo, Paola Galimberti, Michele Bianchi, Stefan-Martin Brand, Oberdan Parodi, Maurizio Lunati.   

Abstract

BACKGROUND: Reverse remodeling (RR) after cardiac resynchronization therapy (CRT) is associated with favorable clinical outcomes in heart failure (HF). The renin-angiotensin-aldosterone system (RAAS) is involved in the remodeling process. METHODS AND
RESULTS: We assessed the association between RR and 8 common RAAS gene variants, which were determined by TaqMan assays, in 156 outpatients with chronic HF. RR was defined as a >15% decrease in left ventricular end systolic volume (LVESV) at 9 (interquartile range 7-12) months after CRT. We matched 76 patients who did not show RR (RR-) to 80 RR+ control subjects by age, sex, HF etiology, New York Heart Association (NYHA) functional class and left ventricular ejection fraction (LVEF). The frequency of the minor allele of the NR3C2 gene (rs5522 C/T), encoding the mineralocorticoid receptor, was higher in RR- than in RR (24/126 vs 10/150; P value after false discovery rate correction: <.0193). Conversely, LVESV decreased significantly less after CRT in carriers of the NR3C2 minor C allele (P = .02). After adjustment for age, sex, NYHA functional class, previous myocardial infarction, atrial fibrillation, and LVEF, RR- remained independently associated with NR3C2 C allele carriage (odds ratio 3.093, 95% confidence interval 1.253-7.632).
CONCLUSIONS: The association of RR- after CRT with a common polymorphism in the mineralocorticoid receptor gene involved in aldosterone signaling suggests a possible role for variants in RAAS genes in progressive LV function decline, despite apparently effective CRT.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23040111     DOI: 10.1016/j.cardfail.2012.07.008

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  4 in total

Review 1.  Recent advances in the optimization of cardiac resynchronization therapy.

Authors:  Satish Chandraprakasam; Gina G Mentzer
Journal:  Curr Heart Fail Rep       Date:  2015-02

Review 2.  Race, common genetic variation, and therapeutic response disparities in heart failure.

Authors:  Mathew R Taylor; Albert Y Sun; Gordon Davis; Mona Fiuzat; Stephen B Liggett; Michael R Bristow
Journal:  JACC Heart Fail       Date:  2014-10-22       Impact factor: 12.035

Review 3.  Pharmacogenomics in heart failure: where are we now and how can we reach clinical application?

Authors:  Akinyemi Oni-Orisan; David E Lanfear
Journal:  Cardiol Rev       Date:  2014 Sep-Oct       Impact factor: 2.644

4.  Cardiac dyssynchrony and response to cardiac resynchronisation therapy in heart failure: can genetic predisposition play a role?

Authors:  N Lahrouchi; C R Bezzina
Journal:  Neth Heart J       Date:  2016-01       Impact factor: 2.380

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.